Business Context and Reporting Period
Company: Transdel Pharmaceuticals, Inc. (Note: Metadata listed "Harrow, Inc." but filing text confirms Transdel Pharmaceuticals, Inc.)
Reporting Period: Quarter ended March 31, 2010
Status: Development Stage Company
Business Overview: Transdel is a specialty pharmaceutical company developing non-invasive, topically delivered products using its patented Transdel™ cream formulation technology. The lead product, Ketotransdel® (ketoprofen), is designed for acute pain management. The company has not generated any revenue since inception and is focused on completing clinical trials and seeking regulatory approval.
Key Financial Metrics
| Metric | Q1 2010 | Q1 2009 | YTD Inception (2010) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(870,612) | $(1,621,236) | $(15,806,181) |
| Operating Expenses | $870,745 | $1,628,025 | $14,822,542 |
| Cash and Equivalents (End of Period) | $951,882 | $4,193,350 | N/A |
| Net Cash Used in Operating Activities | $(637,891) | $(917,681) | $(8,818,513) |
| Total Liabilities | $1,053,912 | $1,094,873 | N/A |
| Stockholders' Deficit | $(35,801) | $577,211 | $(15,806,181) |
Note: The company reported a working capital deficiency as of March 31, 2010, with current liabilities exceeding current assets.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately $750,000 compared to Q1 2009, primarily due to a significant reduction in Research and Development (R&D) expenses.
- R&D Expenses: Dropped from $1.15 million in Q1 2009 to $115,158 in Q1 2010. This decrease reflects the completion of the first Phase 3 clinical trial for Ketotransdel® in the prior year, with only minimal administrative costs incurred in the current quarter.
- Selling, General & Administrative (SG&A) Expenses: Increased by $274,113 to $755,587. This increase was driven by a one-time separation agreement with the former CEO (Dr. Juliet Singh), which included $242,000 in accrued salary/benefits and $174,000 in stock-based compensation for option modifications.
- Liquidity: Cash and cash equivalents declined by approximately $638,000 during the quarter, reducing the balance from $1.59 million to $952,000.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Capital Needs
The company faces a "Going Concern" risk. Management states that continuation as a going concern is dependent on obtaining additional financing. While the company received $1 million in gross proceeds from a Senior Convertible Promissory Note issued on April 5, 2010 (subsequent to the reporting period), this amount is insufficient to fund the second Phase 3 clinical trial required by the FDA for Ketotransdel® approval. Without additional capital, the company may be forced to cease operations.
Management Commentary
- Clinical Progress: The first Phase 3 trial for Ketotransdel® showed statistical significance in a modified Intent-To-Treat (ITT) analysis. However, the FDA requires two adequate and well-controlled Phase 3 trials for approval. The design for the second trial is pending.
- Leadership Change: Dr. Juliet Singh resigned as CEO and Director on February 17, 2010. John Lomoro (CFO) is serving as Acting CEO.
- Cosmeceuticals: The company has licensed its anti-cellulite product to JH Direct, LLC, with a planned launch in the second half of 2010.
Risks and Contingencies
- Regulatory Risk: No assurance that the FDA will accept the modified ITT data from the first trial or that the second trial will be successful.
- Financing Risk: Future equity financing will likely be dilutive. Debt financing may involve restrictive covenants.
- Legal/Contractual: The company has indemnification obligations to directors and officers with no limit on potential future payments, though no liabilities have been recorded historically.
Investor Verification Checklist
- Capital Runway: Verify if the $1 million convertible note received in April 2010 is sufficient to fund operations through the end of 2010 or if immediate additional fundraising is required.
- FDA Stance: Confirm the FDA's official position on the modified ITT analysis of the first Phase 3 trial and the specific requirements for the second trial.
- CEO Search: Monitor the progress of the search for a permanent CEO to replace the acting CEO.
- Stock-Based Compensation: Review the impact of the $174,000 stock-based compensation expense related to the former CEO's separation and the remaining $600,000 of unrecognized compensation expense for unvested options.
- Working Capital: Assess the company's ability to meet current liabilities of $1.05 million given the cash balance of $952,000 and the lack of operating revenue.